000096140 001__ 96140
000096140 005__ 20221004075835.0
000096140 0247_ $$2doi$$a10.3390/nu12103132
000096140 0248_ $$2sideral$$a120719
000096140 037__ $$aART-2020-120719
000096140 041__ $$aeng
000096140 100__ $$aLope, V.
000096140 245__ $$aSerum phospholipids fatty acids and breast cancer risk by pathological subtype
000096140 260__ $$c2020
000096140 5060_ $$aAccess copy available to the general public$$fUnrestricted
000096140 5203_ $$aThis study evaluates whether serum phospholipids fatty acids (PL-FAs) and markers of their endogenous metabolism are associated with breast cancer (BC) subtypes. EpiGEICAM is a Spanish multicenter matched case-control study. A lifestyle and food frequency questionnaire was completed by 1017 BC cases and healthy women pairs. Serum PL-FA percentages were measured by gas chromatography-mass spectrometry. Conditional and multinomial logistic regression models were used to quantify the association of PL-FA tertiles with BC risk, overall and by pathological subtype (luminal, HER2+ and triple negative). Stratified analyses by body mass index and menopausal status were also performed. Serum PL-FAs were measured in 795 (78%) pairs. Women with high serum levels of stearic acid (odds ratio (OR)T3vsT1 = 0.44; 95% confidence interval (CI) = 0.30-0.66), linoleic acid (ORT3vsT1 = 0.66; 95% CI = 0.49-0.90) and arachidonic to dihomo-¿- linolenic acid ratio (OR T3vsT1 = 0.64; 95% CI = 0.48-0.84) presented lower BC risk. Participants with high concentrations of palmitoleic acid (ORT3vsT1 = 1.65; 95% CI = 1.20-2.26), trans-ruminant palmitelaidic acid (ORT3vsT1 = 1.51; 95% CI = 1.12-2.02), trans-industrial elaidic acid (ORT3vsT1 = 1.52; 95% CI = 1.14-2.03), and high oleic to stearic acid ratio (ORT3vsT1 = 2.04; 95% CI = 1.45-2.87) showed higher risk. These associations were similar in all BC pathological subtypes. Our results emphasize the importance of analyzing fatty acids individually, as well as the desaturase activity indices.
000096140 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/IJCI-2014-20900
000096140 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000096140 590__ $$a5.717$$b2020
000096140 591__ $$aNUTRITION & DIETETICS$$b17 / 88 = 0.193$$c2020$$dQ1$$eT1
000096140 592__ $$a1.417$$b2020
000096140 593__ $$aNutrition and Dietetics$$c2020$$dQ1
000096140 593__ $$aFood Science$$c2020$$dQ1
000096140 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000096140 700__ $$aGuerrero-Zotano, A.
000096140 700__ $$aCasas, A.
000096140 700__ $$aBaena-Cañada, J.M.
000096140 700__ $$aBermejo, B.
000096140 700__ $$aPérez-Gómez, B.
000096140 700__ $$aCriado-Navarro, I.
000096140 700__ $$aAntolín, S.
000096140 700__ $$aSánchez-Rovira, P.
000096140 700__ $$aRamos-Vázquez, M.
000096140 700__ $$0(orcid)0000-0002-9159-4988$$aAntón, A.$$uUniversidad de Zaragoza
000096140 700__ $$aCastelló, A.
000096140 700__ $$aGarcía-Saénz, J.A.
000096140 700__ $$aMuñoz, M.
000096140 700__ $$ade Juan, A.
000096140 700__ $$0(orcid)0000-0003-0123-4274$$aAndrés, R.$$uUniversidad de Zaragoza
000096140 700__ $$aLlombart-Cussac, A.
000096140 700__ $$aHernando, B.
000096140 700__ $$aFranquesa, R.M.
000096140 700__ $$aCaballero, R.
000096140 700__ $$aPriego-Capote, F.
000096140 700__ $$aMartín, M.
000096140 700__ $$aPollán, M.
000096140 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000096140 773__ $$g12, 10 (2020), 3132 [18 pp]$$pNUTRIENTS$$tNutrients$$x2072-6643
000096140 8564_ $$s449812$$uhttps://zaguan.unizar.es/record/96140/files/texto_completo.pdf$$yVersión publicada
000096140 8564_ $$s466121$$uhttps://zaguan.unizar.es/record/96140/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000096140 909CO $$ooai:zaguan.unizar.es:96140$$particulos$$pdriver
000096140 951__ $$a2022-10-03-13:25:43
000096140 980__ $$aARTICLE